Los Angeles - 
(NewMediaWire) - March 06, 2022 -The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Talis Biomedical Corporation (“Talis” or “the Company”) (NASDAQ: TLIS) for violations of the federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Talis’ Emergency Use Authorization (“EUA”) application for the Talis One COVID-19 test used a comparator assay of insufficient sensitivity to support the application. This was likely to cause significant delays in the Company’s application achieving approval. This in turn would cause delays in the commercialization of the Company’s product. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
SOURCE:
The Schall Law Firm
View the original release on www.newmediawire.com
